Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(19):1554-1556; doi:10.1093/jnci/92.19.1554
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 19, 1554-1556, October 4, 2000
© 2000 Oxford University Press

NEWS

Model Aims to Reduce Discrepancy Between Phase II, Phase III Trials

Tom Reynolds

The value of an anticancer drug lies in its ability to relieve patients’ symptoms and prolong their lives. How well it does this is the ultimate question posed in testing new agents or regimens.

For a variety of reasons, many promising drugs fall by the wayside on the long march from the chemist’s bench to the oncologist’s armamentarium: What devastates tumor cells in vitro leaves them undaunted in vivo. What works in mice fails in men. Or the cure proves more dreadful than the disease.

Most costly, in terms of money, effort, and time wasted, are drugs or combinations of drugs that first appear powerful in their ability to shrink tumors, but wash out in a randomized clinical trial. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?